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Abstract
Background: Active smoking is the main risk factor for COPD. Here, epigenetic mechanisms may play a role, since
cigarette smoking is associated with differential DNA methylation in whole blood. So far, it is unclear whether
epigenetics also play a role in subjects with COPD who never smoked. Therefore, we aimed to identify differential
DNA methylation associated with lung function in never smokers.
Methods: We determined epigenome-wide DNA methylation levels of 396,243 CpG-sites (Illumina 450 K) in blood
of never smokers in four independent cohorts, LifeLines COPD&C (N = 903), LifeLines DEEP (N = 166), Rotterdam
Study (RS)-III (N = 150) and RS-BIOS (N = 206). We meta-analyzed the cohort-specific methylation results to identify
differentially methylated CpG-sites with FEV1/FVC. Expression Quantitative Trait Methylation (eQTM) analysis was
performed in the Biobank-based Integrative Omics Studies (BIOS).
Results: A total of 36 CpG-sites were associated with FEV1/FVC in never smokers at p-value< 0.0001, but the meta-
analysis did not reveal any epigenome-wide significant CpG-sites. Of interest, 35 of these 36 CpG-sites have not
been associated with lung function before in studies including subjects irrespective of smoking history. Among the
top hits were cg10012512, cg02885771, annotated to the gene LTV1 Ribosome Biogenesis factor (LTV1), and
cg25105536, annotated to Kelch Like Family Member 32 (KLHL32). Moreover, a total of 11 eQTMS were identified.
Conclusions: With the identification of 35 CpG-sites that are unique for never smokers, our study shows that DNA
methylation is also associated with FEV1/FVC in subjects that never smoked and therefore not merely related to
smoking.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is a pro-
gressive inflammatory lung disease characterized by per-
sistent airway obstruction that causes severe respiratory
symptoms and poor quality of life [1]. Although smoking
is generally considered the main environmental risk factor,
estimations are that 25–45% of patients with COPD have
never smoked [2]. Despite extensive research, the etiology
of COPD remains incompletely understood. It is known
that the development of this complex heterogeneous
disease is influenced by both genetic and environmental
factors, as well as their interactions [3–6]. As interface be-
tween the inherited genome and environmental exposures,
an important role has been postulated for the epigenome
[7]. The epigenome includes multiple epigenetic mecha-
nisms that affect gene expression without modifying the
DNA sequence. These epigenetic mechanisms are highly
dynamic and respond to environmental exposures, ageing
and diseases [8]. One such epigenetic mechanism is DNA
methylation, which involves the binding of a methyl group
to a cytosine base located adjacent to a guanine base.
Methylation of these so called CpG-sites in regulatory re-
gions of the DNA generally result in decreased expression
of a particular gene [9].
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: m.de.vries04@umcg.nl
1University of Groningen, University Medical Center Groningen, Department
of Epidemiology, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
2University of Groningen, University Medical Center Groningen, Groningen
Research Institute for Asthma and COPD (GRIAC), Groningen, The
Netherlands
Full list of author information is available at the end of the article
Vries et al. Respiratory Research          (2019) 20:268 
https://doi.org/10.1186/s12931-019-1222-8
So far, only a few studies have investigated the associ-
ation between DNA methylation in peripheral blood and
COPD or lung function using an epigenome-wide hy-
pothesis free approach [10–17]. Although findings across
the studies are not consistent, there is suggestive evi-
dence that alterations in DNA methylation might play a
role in the etiology of COPD. However, in previous stud-
ies, subjects were mainly included irrespective of smok-
ing status, thus including current smokers, ex-smokers
and never smokers. As a consequence, it is currently not
known if there are differences in DNA methylation be-
tween healthy individuals and patients with COPD who
have never smoked. Recently, we studied the association
between epigenome-wide DNA methylation and COPD
in both current smokers and never smokers [16]. Al-
though we did not find any epigenome-wide significant
association in current smokers nor in never smokers, the
associations between DNA methylation and COPD were
different between both groups. Hence, by further explor-
ing the role of DNA methylation in a much larger set of
never smokers together with a continuous measurement
of lung function, we might be able to reveal important
novel insights in the etiology of COPD. In this study, we
aim to assess the association between DNA methylation
and lung function in never smokers, meta-analyzing four
independent population-based cohorts.
Methods
Study population
To study the association between epigenome-wide DNA
methylation and lung function, defined as the ratio be-
tween the Forced Expiratory Volume in 1 s (FEV1) and
Forced Vital Capacity (FVC), in never smokers, we per-
formed a meta-analysis in four different cohorts. Two co-
horts originated from the LifeLines population-based
cohort study [18]: the LifeLines COPD & Controls DNA
methylation study [16, 19] (LL COPD&C, n = 903) and
the LifeLines DEEP study [20] (LLDEEP, n = 166). The
two other cohorts originated from the population-based
Rotterdam study (RS) [21]: The first visit of the third RS
cohort (RS-III-1, n = 150) and a cohort selected for the
Biobank-based Integrative Omics Studies (BIOS) project
(RS-BIOS, n = 206). Both population-based cohort studies
were approved by the local university medical hospital
ethical committees and all participants signed written in-
formed consent. In all cohorts, never smoking was defined
based on self-reported never smoking history and 0 pack
years included in the standardized questionnaires.
Measurements
Lung function
Within the LifeLines population-based cohort study, pre-
bronchodilator spirometry was performed with a Welch
Allyn Version 1.6.0.489, PC-based Spiroperfect with CA
Workstation software according to ATS/ERS guidelines.
Technical quality and results were evaluated by well-trained
assistants and difficult to interpret results were re-evaluated
by a lung physician. Within the population-based Rotterdam
study, pre-bronchodilator spirometry was performed during
the research center visit using a SpiroPro portable spirom-
eter (RS-III-1) or a Master Screen® PFT Pro (RS-BIOS) by
trained paramedical staff according to the ERS/ATS Guide-
lines. Spirometry results were analyzed by two researchers
and verified by a specialist in pulmonary medicine.
DNA methylation
In all four cohorts, DNA methylation levels in whole
blood were determined with the Illumina Infinium
Methylation 450 K array. Data was presented as beta
values (ratio of methylated probe intensity and the over-
all intensity) ranging from 0 to 1. Quality control has
been performed for all datasets separately as described
before [19, 22]. After quality control, data was available
on 396,243 CpG-sites in all four datasets.
Statistical analysis
Epigenome-wide association study and meta-analysis
We performed an epigenome-wide association study
(EWAS) on lung function defined as FEV1/FVC in all
four cohorts separately using robust linear regression
analysis in R. The analysis was adjusted for the potential
confounders age and sex. To adjust for the cellular het-
erogeneity of the whole blood samples, we included pro-
portional white blood cell counts of mononuclear cells,
lymphocytes, neutrophils and eosinophils, obtained by
standard laboratory techniques. For LL COPD&C, we
adjusted for technical variation by performing a principal
components analysis using the 220 control probes
Table 1 Subject characteristics of the subjects from the four different DNA methylation datasets
LL COPD&C LLDEEP RS-III-1 RS-BIOS
Number of subjects, N (%) 903 166 150 206
Male, N (%) 508 (56.3) 71 (42.8) 74 (49.3) 80 (38.8)
Age (yrs), median (min-max) 46 (18–80) 42 (20–78) 63 (53–93) 68 (52–79)
Airway obstruction (FEV1/FVC< 70%), N (%) 316 (35.0) 15 (9.0) 13 (8.7) 19 (9.0)
- FEV1 (L), mean (SE) 3.5 (0.9) 3.6 (0.9) 3.2 (0.8) 2.7 (0.7)
- FEV1/FVC, mean (SE) 84.5 (8.2) 78.6 (6.2) 77.8 (5.9) 77.9 (5.9)
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Fig. 1 Manhattan and forest plots of the meta-analysis on four independent epigenome-wide association studies on FEV1/FVC in never smokers.
a Manhattan plot in which every dot represents an individual CpG-site. Location on the X-axis indicated the chromosomal position and location
on the Y-axis indicates the inversed log [10] p-value of the meta-analysis. Dotted horizontal line indicates p-value of 0.0001, horizontal fixed line
indicates epigenome-wide significance (p-value < 0.05/396,243 = 1.26 × 10^− 7). b-d Forest plots showing the effect estimates and standard errors
of the 4 independent EWA studies and meta-analysis for the top hits cg10012512 (b), cg028885771 (c) and cg25105536 (d)
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incorporated in the Illumina 450 k Chip. The 7 principal
components that explained > 1% of the technical vari-
ation were included in the analysis. For LLDEEP, data
on technical variance was not accessible. For the two RS
cohorts, we included the position on the array and array
number to adjust for technical variation. Regression esti-
mates from all four individual EWA studies were com-
bined by a weighted by the inverse of the variance
random-effect meta-analysis using the effect estimates
and standard errors in “rmeta” package in R. CpG-sites
with a p-value below 1.26 × 10^− 7 (Bonferroni corrected
p-value by number of CpG-sites 0.05/396243) were con-
sidered epigenome-wide significant. CpG-sites with a p-
value below 0.0001 in the meta-analysis were defined as
top associations in our study.
Expression quantitative trait methylation (eQTM) analysis
To assess whether top associations were also associated
with gene expression levels, we used the never smokers
included in the Biobank-based Integrative Omics Studies
(BIOS). For all cohorts separately, reads were normalized
to counts per million. To adjust for technical variation
for gene expression and DNA methylation, principal
component analysis was conducted on the residual nor-
malized counts and beta-values excluding the potential
confounders age and gender. Principal components that
explained more than 5% of the technical variation in
gene expression or DNA methylation were included in
the analysis. Subsequently, robust linear regression ana-
lysis was performed on the CpG-sites and the genes
within 1MB around the CpG-sites. The analyses were
adjusted for the potential confounders age, sex and tech-
nical variation by principal components as stated before.
The individuals eQTM analysis were combined by a
random-effect meta-analysis using the effect estimates
and standard errors in RMeta. An eQTM was consid-
ered significant when the Bonferroni-adjusted p-value
for the number of genes within 1MB around the CpG-
sites was below 0.05.
Results
Subject characteristics
An overview of the characteristics of the subjects included
in the study is shown in Table 1. LL COPD&C was the
largest cohort included in this meta-analysis. Notably,
since this cohort is a non-random selection from the Life-
Lines cohort study with COPD (defined as FEV1/FVC <
0.70) as one of the selection criteria, the percentages of
COPD cases should not be interpreted as prevalence.
Meta-analysis of the four epigenome-wide association
studies
The meta-analysis of the four different cohorts did not re-
veal CpG-sites that were epigenome wide significantly
associated with FEV1/FVC. We identified 36 CpG-sites as
our top associations (Table 2). The Manhattan plot of the
meta-analysis is shown in Fig. 1a. Forest plots of the three
most significant CpG-sites cg10012512, located in the
intergenic region of chromosome 7q36.3 (p=5.94 × 10^− 7),
cg02285771, annotated to LTV1 Ribosome Biogenesis
Factor (LTV1) (p=4.10 × 10^− 6) and cg25105536, anno-
tated to Kelch Like Family Member 32 (KLHL32) (p=
9.09 × 10^− 6) are shown in Fig. 1b-d. An overview of all
CpG-sites associated with FEV1/FVC at nominal p-value
of 0.05 can be found in Additional file 1: Table S1.
The direction of the effect of the 36 top CpG-sites did
not change in a sensitivity analysis in the LL COPD&C
cohort excluding the subjects that were exposed to en-
vironmental tobacco smoke (ETS)(N=659 subjects)
(Additional file 2: Table S2).
Expression quantitative trait methylation (eQTM) analysis
In total, 803 genes were located within 2MB of the 36
CpG-sites. The expression of 11 genes was significantly
Table 3 Overview of the results of the meta-analysis of the eQTM analysis
CpG-site Gene annotation
CpG-site
Genes located
within 1 MB (N)
Gene (expression) Beta SE p-value Adjusted p-value
cg02137691 FGFR3 31 SLC26A1 0.0156 0.0038 3.53E-05 0.0011
cg02206852 PROCA1 52 NUFIP2 0.0084 0.0022 1.06E-04 0.0055
cg02206852 PROCA1 52 GIT1 0.0080 0.0023 6.11E-04 0.0318
cg02885771 LTV1 11 VDAC1P8 0.0096 0.0033 3.51E-03 0.0386
cg07148038 TNXB 89 ATP6V1G2 0.0074 0.0021 3.79E-04 0.0337
cg07148038 TNXB 89 STK19B 0.0035 0.0010 3.77E-04 0.0335
cg08065963 12 ABAT 0.0127 0.0034 1.85E-04 0.0022
cg20939319 TEX15 10 SARAF −0.0029 0.0010 3.36E-03 0.0336
cg22127773 KDM6B 80 TMEM88 0.0011 0.0003 1.82E-04 0.0146
cg23396786 SFXN5 18 CYP26B1 0.0024 0.0008 1.78E-03 0.0321
cg25105536 KLHL32 4 KLHL32 −0.0004 0.0002 5.52E-03 0.0221
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Table 4 Overview of studies reporting results of differential DNA methylation with lung function or COPD in whole blood
Study Study population Trait Adjustment
included
in model
DNA methylation
platform
Number of
CpG-sites
available for
comparison
Epigenome-wide
association study of
lung function level
and its change
Imboden et al., 2019 [17]
Discovery-replication approach.
Discovery included 3 cohorts
(N=2043) and replication included
7 cohorts (Adult: N=3327,
Childhood: N=420)
- Smoking status: self-reported,
subjects with and without smoking
history; never smokers only
- FEV1
- FVC
- FEV1/FVC
Analyses were performed
twice: with and without
adjustment for smoking status
and pack years
- Age
- Age2
- Height
- Height2
deviation
- Sex
- Sex Age,
Age2,
height,
Height2
deviation
- Education
- BMI
- Spirometer
type
- Study
Center
- Blood cell
composition
Discovery: Illumina
Infinium Human
Methylation 450 K
BeadChip and EPIC
BeadChip
Replication: various
arrays for the
discovery-identified
CpG-sites only
Without
smoking
adjustment:
56a
With
smoking
adjustment:
12a
Never
smokers: 8
(from
discovery).
None of the
CpG sites
were
replicateda
No association
between DNA methylation
and COPD in never
and current smokers
De Vries et al., 2018 [16]
Non-random selection from
LifeLines cohort (N=1561 subjects)
- Smoking status: Stratified for smoking
(658 smokers and 903 never smokers)
- COPD
(defined as FEV1/FVC ≤ 0.7)
- Sex
- Age
- Pack years
(in smoking
stratified
analysis)
- Batch effects
- Blood cell
composition
Illumina Infinium
Human
Methylation450K
BeadChip array
- Number of
included probes:
420,938
Smokers:
19492b
Never
smokers:
19393b
Lung function discordance
in monozygotic twins and
ssociated differences in
blood DNA methylation
Bolund et al., 2017 [11]
Sub-population of twins from the
Middle-Aged Danish Twin (MADT)
study (N=169 twin pairs)
- Smoking status: subjects with and
without smoking history
Intra-pair difference in z-score
calculated as “superior” minus
“inferior” twin at baseline and
during follow-up period for:
- FEV1
- FVC
- FEV1/FVC
- Sex
- Age
- BMI
- Pack years
- Smoking
status at
follow-up
- Blood cell
composition
Intra-pair
difference
was
calculated for
all the
variables
Illumina Infinium
Human
Methylation450K
BeadChip array
- Number of
included probes:
453,014
37a
Epigenome-wide association
study of chronic obstructive
pulmonary disease and lung
function in Koreans
Lee et al., 2017 [12]
Sample of Korean COPD cohort
(N=100 subjects)
- Smoking status: subjects with
and without smoking history
- COPD status
(defined as FEV1/FVC < 0.7)
- FEV1
- FVC
- FEV1/FVC
- Sex
- Age
- Height
- Smoking
status
- Pack years
- Blood cell
composition
Illumina Infinium
Human
Methylation450K
BeadChip array
- Number of
included probes:
402,508
16a
Differential DNA methylation
marks and gene comethylation
of COPD in African-Americans
with COPD exacerbations
Busch et al., 2016 [13]
Sample of PA-SCOPE AA
study population
(N=362 subjects)
- Smoking status: smokers
> 20 pack years
- COPD
(defined as FEV1/FVC ≤ 0.7
and FEV1 ≤ 80%)
- Sex
- Age
- Pack years
- Batch
number
- Blood cell
composition
Illumina Infinium
Human
Methylation27K
BeadChip array
- Number of
included probes:
19,302
12a
The epigenetic clock is
correlated with physical
and cognitive fitness
in the Lothian Birth Cohort
Marioni et al., 2015 [15]
The Lothian Birth Cohort
of 1936
(N=1091)
- Smoking status: self-reported,
subjects with and without
smoking history
- FEV1 - Sex
- Age
- Height
- Smoking
status
- Blood cell
composition
Illumina Infinium
Human
Methylation450K
BeadChip array
- Number of
included probes:
450,726
2a
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associated with DNA methylation levels at the 9 different
CpG-sites (Table 3). DNA methylation at cg25105536,
annotated to KLHL32, was significantly associated with
gene expression levels of KLHL32. DNA methylation
levels at cg08065963, located in the intergenic region on
chromosome 16 and not yet annotated to a gene, showed
a significant association with gene expression levels of
4-Aminobutyrate Aminotransferase (ABAT). For the other
7 CpG-sites, DNA methylation levels were associated with
gene expression levels of one or two genes other than the
previously annotated genes. An overview of the association
between DNA methylation and gene expression levels of
all genes can be found in Additional file 3: Table S3.
Discussion
This study is the first large general population-based
EWA study on lung function in never smokers. So far, vir-
tually all EWA studies on the origin of COPD included
subjects with a history of cigarette smoking. As a conse-
quence, these studies mainly addressed the origins of
COPD in response to smoking. It is unclear if the results
of these studies help to explain the etiology of COPD or
rather explain the contribution of cigarette smoke towards
the disease. Therefore, our study importantly contributes
to the current understanding of COPD in never smokers.
We identified 36 CpG-sites that were significantly as-
sociated with FEV1/FVC at p-value below 0.0001. The
top hit of our meta-analysis, cg10012512, is located in
the intergenic region of chromosome 7q36.3. It is there-
fore not possible to speculate on the functional effect of
differences in DNA methylation at this specific CpG-site
and how these differences may affect FEV1/FVC. While
associations found with an eQTM analysis may help to
get more insight in the function of a CpG-site, our
eQTM analysis did not reveal any nominal significant
associations for cg10012512. However, this CpG-site was
differentially methylated between never smokers and
current smokers [23]. Presumably, this CpG-site does
also respond to other inhaled deleterious substances,
which in turn affects lung function. The second top hit,
cg02885771 located on chromosome 6q24.2 is annotated
LTV1. Previously, this CpG-site has been associated with
asthma in airway epithelial cells [24] and LTV1 was
shown to be expressed in lung tissue in the Genotype
Tissue Expression (GTEx) project. Although studies in
yeast describe LTV1 as a conserved 40S-associated bio-
genesis factor that functions in small subunit nuclear
export, a specific role for LTV1 in respiratory diseases is
not known [25]. The third top hit, cg25105536, is anno-
tated to KLHL32 on chromosome 6q16.1 and we found
a significant association between DNA methylation
levels of cg25105536 and gene expression levels of
KLHL32. The function of KLHL32 is poorly understood,
however, four genetic variants in the KLHL32 gene have
been associated with FEV1 and FEV1/FVC in African
American subjects with COPD and a history of smoking
[26]. Notwithstanding the fact that these associations
were only identified in a specific group, it might suggest
a role for KLHL32 in the respiratory system. Next to
KLHL32, we found that gene expression levels of 10
additional genes were significantly associated with DNA
methylation levels at one of the 36 CpG-sites. cg08065963,
which was not yet annotated to a gene, was significantly as-
sociated with 4-Aminobutyrate Aminotransferase (ABAT).
Interestingly, a role for ABAT in COPD has not been de-
scribed before. The remaining nine genes were other genes
than the annotated genes of the particular CpG-sites. This
suggest that the CpG-sites may also regulate distant genes
within a region of 2MB, which complicates the functional
assessment of differences in DNA methylation even further.
Table 4 Overview of studies reporting results of differential DNA methylation with lung function or COPD in whole blood
(Continued)
Study Study population Trait Adjustment
included
in model
DNA methylation
platform
Number of
CpG-sites
available for
comparison
Variable DNA methylation
is associated with
chronic obstructive
pulmonary disease and
lung function
Qiu et al., 2012 [10]
Test-replication approach in 2
family-based cohorts
(N=1085 and 369 subjects)
- Smoking status: subjects with
and without smoking history
- COPD status (FEV1/FVC ≤0.7
and FEV1 ≤70%)
- FEV1/FVC
- FEV1
- Random
family effect
Illumina Infinium
Human
Methylation27K
BeadChip array
- Number of
included probes:
26,485
349a
Epigenome-wide scans
identify differentially
methylated regions for
age and age-related
phenotypes in a healthy
ageing population
Bell et al., 2012 [14]
Sample of the TwinsUK cohort
(N=172 female twin pairs)
- Smoking status: unknown
- FEV1
- FVC
- Age
- Batch effects
Illumina Infinium
Human
Methylation27K
BeadChip array
- Number of
included probes:
24,641
1a
COPD Chronic Obstructive Pulmonary Disease, FEV1 Forced Expiratory Volume in 1 s, FVC Forced Expiratory Capacity
aCpG-sites obtained from the online available data
bCpG-sites selected at nominal p-value < 0.05 available from self-performed analyses
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Table 5 Overview of CpG location, gene annotation, gene function and literature comparison of the top 36 CpG-sites of the meta
analysis
CpG-site CpG location Gene annotation Gene function Previously associated
with lung function
cg10012512 7:157224041 Intergenic NA Yesa
cg02885771 6:144163654 LTV1 Involved in ribosome biogenesis No
cg25105536 6:97372436 KLHL32 Only described as protein coding gene No
cg20102034 2:74653166 RTKN Negative regulator of GTPase activity of
Rho proteins
Yesa
cg03703840 11:93394809 KIAA1731 Mediating of centriole-to-centrosome
conversion at late mitosis
No
cg21614201 4:119888794 SYNPO2 Only described as protein coding gene No
cg07957088 20:62196387 PRIC285 Nuclear transcriptional co-activator for
peroxisome proliferator activated
receptor alpha
Yesa
cg05304461 1:11019377 C1orf127 Only described as protein coding gene No
cg11749902 8:41093619 Intergenic NA Yesa
cg02207312 11:60674164 PRPF19 Involved in cell survival and DNA repair No
cg19734370 17:78444348 NPTX1 Exclusively localized to the nervous system
as binding protein for taipoxin
Yesa
cg03077331 17:80693076 FN3K Catalyzes the phosphorylation of fructosamines Yesa
cg18387671 17:27920246 ANKRD13B Only described as protein coding gene Yesa
cg03224276 16:72829831 ZFHX3 Regulates myogenic and neuronal differentiation No
cg02137691 4:1805671 FGFR3 Involved in bone development and maintenance No
cg25884324 15:91482502 UNC45A Regulator of the progesterone receptor
chaperoning pathway
No
cg27158523 6:149867355 PPIL4 Involved in protein folding, immunosuppression
and infection of HIV-1 virions
Yesa
cg01157143 11:19478542 NAV2 Plays a role in cellular growth and migration No
cg07160694 14:69619856 DCAF5 Only described as protein coding gene No
cg22127773 17:7754785 KDM6B Demethylation of di- or tri-methylated lysine
27 of histone H3
Yesa
cg20939319 8:30707701 TEX15 Involved in cell cycle processes of spermatocytes No
cg02206852 17:27030540 PROCA1 Only described as protein coding gene No
cg17075019 10:79541650 Intergenic NA Yesa
cg25556432 2:239628926 Intergenic NA Yesa
cg22742965 2:192891657 TMEFF2 Cellular context-dependent oncogene or
tumor suppressor
Yes
cg16734845 15:44781962 CTDSPL2 Only described as protein coding gene No
cg09108394 16:23850106 PRKCB As kinase involved in diverse cellular
signaling pathways
No
cg10034572 2:160921789 Intergenic NA No
cg20066227 10:16564552 C1QL3 Only described as protein coding gene No
cg07148038 6:32061160 TNXB Anti-adhesive protein involved in matrix
maturation during wound healing
Yesa
cg23396786 2:73299151 SFXN5 Only described as protein coding gene Yesa
cg06218079 17:80834228 TBCD As co-factor D involved in the correct
folding of beta-tubulin
No
cg06982745 10:72454006 ADAMTS14 The matured enzyme is involved in the
formation of collagen fibers
No
cg05946118 16:8985638 Intergenic NA Yesa
cg08065963 16:8985593 Intergenic NA Yesa
cg12064372 12:30948792 Intergenic NA Yesa
aOnly observed in study by de Vries et al. in never smokers; Gene function obtained by www.genecards.org
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To the best of our knowledge, there are eight studies
in literature describing the association between DNA
methylation and lung function (Table 4). Six of these
studies included both subjects with and without a
history of cigarette smoking and, except for the study
by Qui et al., adjusted for smoking status in the statis-
tical analysis. In addition, the recent study by Imboden
et al. performed analyses with and without adjustment
for smoking status and pack years. Altogether, these
seven studies identified 462 unique CpG-sites. Interest-
ingly, none of the 36 CpG-sites from our meta-analysis in
never smokers were among these 462 previously identified
CpG-sites (Table 5). Apparently these 36 CpG-sites are
only associated with lung function level in never smokers.
The fact that 17 CpG-sites (47%) were associated at nom-
inal p-value < 0.05 with COPD (dichotomously defined as
the ratio of FEV1/FVC below 70%) in our previously
EWAS stratified for never smoking, further underscores
this assumption [16]. There is, however, one exception,
since cg22742965, annotated to Transmembrane Protein
With EGF Like And Two Follistatin Like Domains 2
(TMEFF2), was also significantly associated with COPD in
smokers. Most likely, this CpG-site shows a general re-
sponse to inhaled deleterious substances such as cigarette
smoke and other yet unknown substances.
Assuming that the observed differential DNA methyla-
tion at the majority of the CpG-sites in our study occurs
without exposure to smoking, the question arises why this
differential DNA methylation is observed. One possible
explanation may be that other factors within the environ-
ment such as air pollution and job-related exposures are
responsible for the observed differences in DNA methyla-
tion. Recently, we studied the epigenome-wide association
between DNA methylation and exposure to air pollution
and job-related exposures in a selection of the LifeLines
population cohort including both never and current
smokers [19, 27]. While we did find significant associa-
tions, none of them were replicated in independent co-
horts. Additional analyses in never smokers for this paper
did not reveal novel associations between DNA methyla-
tion and environmental exposures (Additional file 4: Table
S4 and Additional file 5: Figure S1). This might poten-
tially be due to lack of power, since only a small per-
centage of the subjects that have never smoked in the
LL COPD&C cohort have been exposed to environ-
mental exposures. Moreover, exposure levels to air
pollution in the LL COPD&C are relatively low com-
pared to the average Dutch levels determined within
the 2012 Dutch national health survey as described
by Strak et al [28]. Next to environmental exposures,
another explanation may be that a reduced lung func-
tion level precedes the differences in DNA methyla-
tion. However, with the cross-sectional design of this
study, we cannot derive conclusions on the direction of
the association and causality. Large longitudinal studies
are required to investigate causality between DNA methy-
lation and FEV1/FVC. Moreover, this will give the oppor-
tunity to investigate if low levels of FEV1 and decline in
FEV1 over the years is associated with DNA methylation
in never smokers.
Conclusions
With this study we show that epigenetics indeed may be as-
sociated with FEV1/FVC in subjects who never smoked.
Moreover, since 35 out of the 36 identified CpG-sites are
unique for never smokers, our data suggest that factors
other than smoking affect FEV1/FVC via DNA methylation.
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